Company: RPTX
Filing Date: 2025-10-22
Form Type: 8-K
Source: 0001193125-25-246226
Chunk: 0

Company: Repare Therapeutics Inc.
Filing Date: 2025-10-22
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On October 22, 2025, Repare Therapeutics Inc. (the "Company") announced that the abstract related to the Company’s Phase 1 LIONS trial of RP-1664 was made available. The preliminary data in the abstract will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The abstract is available under the “ Scientific References” tab of the “ Science” section of the Company’s website under the title “ Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification.”

The information contained herein is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

The Company’s website and any information contained on the Company’s website are not incorporated into this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                            REPARE THERAPEUTICS INC.                                        
  Date:      October 22, 2025      By:      /s/ Steve Forte                                                 
                                            Steve Forte